Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Dominika Wcisło-Dziadecka; Beniamin Grabarek; Andrzej Swinarew; Beata Rozwadowska; Nikola Zmarzły; Joanna Gola

doi:10.5114/ada.2020.94847

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2020
vol. 37

Send email

Copy url:

abstract:

Original paper

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Dominika Wcisło-Dziadecka

¹

,

Beniamin Grabarek

^{2, 3}

,

Andrzej S. Swinarew

⁴

,

Beata Rozwadowska

¹

,

Nikola Zmarzły

^{2, 5}

,

Joanna Gola

⁵

Department of Cosmetology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
Department of Histology, Cytophysiology and Embryology, Faculty of Medicine in Zabrze, University of Technology in Katowice, Poland
Department of Clinical Trials, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland
Institute of Materials Science, Faculty of Computer Science and Material Science, University of Silesia, Katowice, Poland
Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland

Adv Dermatol Allergol 2020; XXXVII (2):262–268

DOI: https://doi.org/10.5114/ada.2020.94847

Online publish date: 2020/05/06

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Wcisło-Dziadecka D, Grabarek B, Swinarew AS, Rozwadowska B, Zmarzły N, Gola J. Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(2):262-268. doi:10.5114/ada.2020.94847.

APA

Wcisło-Dziadecka, D., Grabarek, B., Swinarew, A. S., Rozwadowska, B., Zmarzły, N.,  & Gola, J. (2020). Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(2), 262-268. https://doi.org/10.5114/ada.2020.94847

Chicago

Wcisło-Dziadecka, Dominika, Beniamin Grabarek, Andrzej S Swinarew, Beata Rozwadowska, Nikola Zmarzły,  and Joanna Gola. 2020. "Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 37 (2): 262-268. doi:10.5114/ada.2020.94847.

Harvard

Wcisło-Dziadecka, D., Grabarek, B., Swinarew, A., Rozwadowska, B., Zmarzły, N.,  and Gola, J. (2020). Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(2), pp.262-268. https://doi.org/10.5114/ada.2020.94847

MLA

Wcisło-Dziadecka, Dominika et al. "Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 37, no. 2, 2020, pp. 262-268. doi:10.5114/ada.2020.94847.

Vancouver

Wcisło-Dziadecka D, Grabarek B, Swinarew A, Rozwadowska B, Zmarzły N, Gola J. Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(2):262-268. doi:10.5114/ada.2020.94847.

Introduction
Adalimumab and etanercept are drugs used in anti-TNF therapy in patients with psoriasis and psoriatic arthritis. Despite the molecular targeting of these drugs, the loss of pharmacological response to treatment is observed in patients. The development of personalized medicine makes it possible to use not only clinical parameters of disease severity, but also molecular marker systems.

Aim
The aim of the study was to evaluate the changes in TNF-α TNFR1, and TNFR2 expression in relation to parameters of disease severity (PASI, BSA, DAS28) in patients treated with adalimumab and etanercept. We have attempted to determine whether changes in the TNF-α, TNFR1, and TNFR2 expression profile may be a useful molecular marker of the therapeutic potential of anti-TNF drugs.

Material and methods
The study group consisted of 3 patients initially treated with adalimumab, followed by etanercept. The control group included 20 healthy volunteers. The expression profile of TNFR1 and TNFR2 was determined at the mRNA level, while TNF-α expression was evaluated at the transcriptome and proteome levels using the RT-qPCR method (transcriptional activity assay) and MALDI-TOF MS (protein level assessment).

Results
Depending on the drug, different expression profiles of the studied cytokines are observed.

Conclusions
The obtained data indicate that TNF-α, TNFR1, and TNFR2 may be useful markers of the efficacy of anti-TNF therapy, thus complementing clinical parameters.

keywords:

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Dominika Wcisło-Dziadecka 1 , Beniamin Grabarek 2, 3 , Andrzej S. Swinarew 4 , Beata Rozwadowska 1 , Nikola Zmarzły 2, 5 , Joanna Gola 5

anti-TNF therapy, psoriasis, molecular marker, resistance in therapy, personalized medicine

Dominika Wcisło-Dziadecka

¹

,

Beniamin Grabarek

^{2, 3}

,

Andrzej S. Swinarew

⁴

,

Beata Rozwadowska

¹

,

Nikola Zmarzły

^{2, 5}

,

Joanna Gola

⁵